FDA panel to discuss Immunomedics agent

Article

A Food and Drug Administration advisory committee is set to meetFeb. 16 to discuss CEA-Scan, a monoclonal antibody imaging agentfor colorectal cancer developed by Immunomedics. Immunomedics,of Morris Plains, NJ, has been working with the FDA on the

A Food and Drug Administration advisory committee is set to meet

Feb. 16 to discuss CEA-Scan, a monoclonal antibody imaging agent

for colorectal cancer developed by Immunomedics. Immunomedics,

of Morris Plains, NJ, has been working with the FDA on the agent's

product license application (PLA) since the agency said the PLA

was not approvable in 1994 (SCAN 6/1/94).

Related Videos
Practical Insights on CT and MRI Neuroimaging and Reporting for Stroke Patients
Emerging Innovations in Molecular Imaging
Related Content
© 2023 MJH Life Sciences

All rights reserved.